Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis

Abstract

We have demonstrated that nuclear factor-κB (NF-κB) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized, nontumorigenic pancreatic epithelial cells, suggesting that NF-κB plays a critical role in the development of pancreatic adenocarcinoma. To elucidate the role of constitutive NF-κB activity in human pancreatic cancer cells, we generated pancreatic tumor cell lines that express a phosphorylation defective IκBα (S32, 36A) (IκBαM) that blocks NF-κB activity. In this study, we showed that inhibiting constitutive NF-κB activity by expressing IκBαM suppressed the tumorigenicity of a nonmetastatic human pancreatic cancer cell line, PANC-1, in an orthotopic nude mouse model. Immunohistochemical analysis showed that PANC-1-derived tumors expressed vascular endothelial growth factor (VEGF) and induced angiogenesis. Inhibiting NF-κB signaling by expressing IκBαM significantly reduced expression of Bcl-xL and Bcl-2. The cytokine-induced expression of VEGF and Interleukin-8 in PANC-1 cells is also decreased. Taken together, these results suggest that the inhibition of NF-κB signaling can suppress tumorigenesis of pancreatic cancer cells and that the NF-κB signaling pathway is a potential target for anticancer agents.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Baldwin Jr AS . (1996). Annu. Rev. Immunol., 14, 649–683.

  • Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C and Neoptolemos JP . (1995). Br. J. Surg., 82, 111–115.

  • Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW and Evans DB . (2001). Ann. Surg. Oncol., 8, 123–132.

  • Chang TC, Hung MW, Jiang SY, Chu JT, Chu LL and Tsai LC . (1997). FEBS Lett., 415, 11–15.

  • Chiao PJ, Miyamoto S and Verma IM . (1994). Proc. Natl Acad. Sci. USA, 91, 28–32.

  • Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP and Bours V . (1995). Oncogene, 11, 1835–1841.

  • Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ and Chiao PJ . (2002). Oncogene, 21, 6510–6519.

  • Ferrara N . (1995). Breast Cancer Res. Treat., 36, 127–137.

  • Folkman J . (1990). J. Natl. Cancer Inst., 82, 4–6.

  • Folkman J . (1992). Semin. Cancer Biol., 3, 65–71.

  • Folkman J, Watson K, Ingber D and Hanahan D . (1989). Nature, 339, 58–61.

  • Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Q1Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ . (2003). Clin. Cancer Res., 9, 346–354.

  • Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK and Seed B . (1998). Cell, 94, 715–725.

  • Gilmore TD, Koedood M, Piffat KA and White DW . (1996). Oncogene, 13, 1367–1378.

  • Grau AM, Zhang L, Wang W, Ruan S, Evans DB, Abbruzzese JL, Zhang W and Chiao PJ . (1997). Cancer Res., 57, 3929–3934.

  • Grisham MB, Palombella VJ, Elliott PJ, Conner EM, Brand S, Wong HL, Pien C, Mazzola LM, Destree A, Parent L and Adams J . (1999). Methods Enzymol, 300, 345–363.

  • Hu DE, Hori Y and Fan TP . (1993). Inflammation, 17, 135–143.

  • Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ . (2001). Oncogene, 20, 4188–4197.

  • Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ . (2000). Cancer Res., 60, 5334–5339.

  • Jemal A, Thomas A, Murray T and Thun M . (2002). CA Cancer J. Clin., 52, 23–47.

  • Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X and Nerenberg M . (1992). Science, 258, 1792–1795.

  • Klingler K, Tchou-Wong KM, Brandli O, Aston C, Kim R, Chi C and Rom WN . (1997). Infect. Immun., 65, 5272–5278.

  • Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG and Strieter RM . (1992). Science, 258, 1798–1801.

  • Lee TH, Avraham H, Lee SH and Avraham S . (2002). J. Biol. Chem., 277, 10445–10451.

  • Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J and Harris AL . (1996). Cancer Res., 56, 4625–4629.

  • Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V and Nuseir N . (1987). Nature, 329, 630–632.

  • Liotta LA, Steeg PS and Stetler-Stevenson WG . (1991). Cell, 64, 327–336.

  • Lu D, Thompson JD, Gorski GK, Rice NR, Mayer MG and Yunis JJ . (1991). Oncogene, 6, 1235–1241.

  • Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W and Ullrich A . (1993). Cell, 72, 835–846.

  • Mohammad RM, Adsay NV, Philip PA, Pettit GR, Vaitkevicius VK and Sarkar FH . (2001). Anticancer Drugs, 12, 735–740.

  • Moore BE and Bose Jr HR . (1988). Virology, 162, 377–387.

  • Mukaida N, Mahe Y and Matsushima K . (1990). J. Biol. Chem., 265, 21128–21133.

  • Naviaux RK, Costanzi E, Haas M and Verma IM . (1996). J. Virol., 70, 5701–5705.

  • Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RS and Dalla-Favera R . (1991). Cell, 67, 1075–1087.

  • Ohno H, Takimoto G and McKeithan TW . (1990). Cell, 60, 991–997.

  • Parborell F, Pecci A, Gonzalez O, Vitale A and Tesone M . (2002). Biol. Reprod., 67, 481–486.

  • Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS and Martin GR . (1992). Lab. Invest., 67, 519–528.

  • Sawai H, Yamamoto M, Okada Y, Sato M, Akamo Y, Takeyama H and Manabe T . (2001). Pancreas, 23, 399–405.

  • Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Luttges J, Kloppel G, Graeven U, Eilert-Micus C, Hintelmann A and Schmiegel W . (2000). Proc. Natl. Acad. Sci. USA, 97, 9624–9629.

  • Shono T, Ono M, Izumi H, Jimi SI, Matsushima K, Okamoto T, Kohno K and Kuwano M . (1996). Mol. Cell Biol., 16, 4231–4239.

  • Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE, Polverini PJ and Elner SG . (1992). Am. J. Pathol., 141, 1279–1284.

  • Sylla BS and Temin HM . (1986). Mol. Cell Biol., 6, 4709–4716.

  • Teraoka H, Sawada T, Nishihara T, Yashiro M, Ohira M, Ishikawa T, Nishino H and Hirakawa K . (2001). Br.J. Cancer, 85, 612–617.

  • Tsai LC, Hung MW, Chang GG and Chang TC . (2000). Anticancer Res., 20, 2441–2448.

  • Tsuzuki Y, Mouta Carreira C, Bockhorn M, Xu L, Jain RK and Fukumura D . (2001). Lab. Invest., 81, 1439–1451.

  • Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S . (1995). Genes Dev., 9, 2723–2735.

  • Wang W, Abbruzzese JL, Evans DB and Chiao PJ . (1999a). Oncogene, 18, 4554–4563.

  • Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ . (1999b). Clin. Cancer Res., 5, 119–127.

  • Xu Z, Friess H, Solioz M, Aebi S, Korc M, Kleeff J and Buchler MW . (2001). Int. J. Cancer, 94, 268–274.

  • Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J . (2000). Nature, 407, 242–248.

  • Yoshida A, Yoshida S, Ishibashi T, Kuwano M and Inomata H . (1999). Invest. Ophthalmol. Vis. Sci., 40, 1624–1629.

  • Yoshimura T, Matsushima K, Oppenheim JJ and Leonard EJ . (1987). J. Immunol., 139, 788–793.

Download references

Acknowledgements

We thank Mariann Crapanzano for editorial assistance. This work was supported in part by grants CA73675, CA78778, and CA 75517 from the National Cancer Institute (NCI), and a grant from the Lockton Fund for Pancreatic Cancer Research. WAF is a recipient of the NCI T32 Training Grant Fellowship, and GMS is a recipient of a Fellowship of the Cancer League of Bern, Switzerland.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul J Chiao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujioka, S., Sclabas, G., Schmidt, C. et al. Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene 22, 1365–1370 (2003). https://doi.org/10.1038/sj.onc.1206323

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206323

Keywords

This article is cited by

Search

Quick links